Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
NCT ID: NCT06052254
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
150 participants
INTERVENTIONAL
2025-09-16
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible subjects will be screened up to 21 days prior to study start.
Eligible subjects will be randomized 1:1:1 to treatment with 1 DMTS and 1 matching placebo, 2 DMTS, or 2 matching placebos.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
For the second dosing period, subjects will receive the same treatment administered as the first dosing period. An independent data monitoring committee will periodically review safety data to confirm the safety/tolerability of the dose. Subjects will reside in their care facility for the duration of the trial. The following assessments will be performed: agitation assessments (frequency and severity); sedation-level assessments; safety assessments (vital signs including oxygen saturation by pulse oximetry (SpO2)); DMTS/matching placebo adhesion assessments; and skin irritation assessments. In addition, blood samples will be collected for determination of plasma concentrations of dexmedetomidine.
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
12 cm2 - 2 Active DMTS Patches
2 Active DMTS patches will be applied to the upper back and worn for 4 days (96 hours) followed 14 days later with the same treatment for an additional 4-day treatment for subjects that are eligible for a second dosing.
12 cm2 - 2 Active DMTS Patches
2 Active DMTS patches applied to the upper back followed 14 days later by another application of 2 Active DMTS patches. Each application will be worn for 4 days (96 hours)
6 cm2 - 1 Active and 1 Placebo DMTS Patches
1 Active and 1 Placebo DMTS patches will be applied to the upper back and worn for 4 days (96 hours) followed 14 days later with the same treatment for an additional 4-day treatment period for subjects that are eligible for a second dosing.
6 cm2 - 1 Active and 1 Placebo DMTS Patches
1 Active and 1 Placebo DMTS patches applied to the upper back followed 14 days later by another application of 1 Active and 1 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
Placebo - 2 Placebo DMTS Patches
2 Placebo DMTS patches will be applied to the upper back and worn for 4 days (96 hours) followed 14 days later with the same treatment for an additional 4-day treatment period for subjects that are eligible for a second dosing.
Placebo - 2 Placebo DMTS Patches
2 Placebo DMTS patches applied to the upper back followed 14 days later by another application of 2 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
12 cm2 - 2 Active DMTS Patches
2 Active DMTS patches applied to the upper back followed 14 days later by another application of 2 Active DMTS patches. Each application will be worn for 4 days (96 hours)
6 cm2 - 1 Active and 1 Placebo DMTS Patches
1 Active and 1 Placebo DMTS patches applied to the upper back followed 14 days later by another application of 1 Active and 1 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
Placebo - 2 Placebo DMTS Patches
2 Placebo DMTS patches applied to the upper back followed 14 days later by another application of 2 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female, residing in a care facility.
3. Has a diagnosis of dementia of probable Alzheimer's Disease (AD) based on National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria (2018). The clinical diagnosis of "probable Alzheimer's Disease (AD)" will be based on the 2018 National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria, which includes patient biomarker data as part of the research diagnosis (Jack et al., 2018). If patient biomarker data are unavailable, per the 2018 NIA-AA diagnostic criteria, the clinical diagnosis of probable AD will be based on the 2011 NIA-AA criteria (McKhann et al., 2011).
4. Had two or more episodes (using a 7-day lookback period) of agitation that impairs social activities, requires staff or medical intervention, or impairs ability for functional activities of daily living at Screening.
5. Had an ABS total score ≥ 22 at least once during Day -4 to Day -1 when assessing eligibility on Day 1 Pre-randomization.
6. Has gone a minimum of 1 week with no change in medication prior to Screening.
7. Has a score of ≤ 23 on the Mini-Mental State Examination (MMSE) at Screening.
8. Female subjects who are:
1. Not pregnant, not lactating, and not planning to become pregnant during the study or for 1 menstrual cycle thereafter and
2. Surgically sterile; or postmenopausal (ie, amenorrhea for ≥2 years as reported by subject/caregiver; postmenopausal status will be confirmed with FSH test); or have a monogamous partner who is surgically sterile; or have a same gender sex partner; or is using double-barrier contraception; or practicing abstinence; or using an insertable, injectable, transdermal, or combination oral contraceptive for 3 months prior to the study, during the study, and for 1 month following the study.
9. Male subjects who have female sex partners of childbearing potential must be surgically sterile or commit to use a reliable method of birth control during the study and for 1 month following the study. Reliable contraception is defined as: A tubal ligation, condom with spermicidal gel, an approved hormonal contraceptive such as oral contraceptives, emergency contraception used as directed, patches, implants, injections, rings, or hormone releasing or copper intrauterine device (IUD).
10. Has a body weight \> 50 kg, and body mass index of 20 to 38 kg/m2, inclusive.
11. Subject or LAR able to understand the study procedures, comply with all study procedures, and agree to participate in the study program for its full duration.
12. Has lived in facility for at least 7 days prior to screening and will remain in facility through the completion of Follow-Up assessments.
Exclusion Criteria
2. Has a skin abnormality (eg, scar, tattoo) or unhealthy skin condition (eg, burns, wounds) at the DMTS/matching placebo application site, according to examination by the investigator at screening.
3. Has a clinically significant abnormal clinical laboratory test value as determined by the investigator.
4. Has agitation caused by acute intoxication.
5. Has significant risk of suicide or homicide per investigator's assessment, or any patient with an answer of "yes" to Items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS).
6. Has a history of or positive test results for the human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
7. Has a clinically significant history or clinically significant manifestation of any of the following, as determined by the investigator: a renal (including an estimated glomerular filtration rate \[eGFR\] below the appropriate age- and gender-specific range \[see Section 8.1.3.2\]), hepatic (including any evidence of ascites and/or a Child-Pugh hepatic impairment score \> 6 \[Appendix G\]), cardiovascular, metabolic, neurologic, or psychiatric condition; congestive heart failure, peptic ulcer, gastrointestinal bleeding, or other condition that may preclude participation in the study.
8. Has a history of physician-diagnosed migraine, frequent non-vascular headaches (\> 5 per month), seizures, or are currently taking anticonvulsants.
9. Has a history of syncope or other syncopal attacks.
10. Has present and/or significant history of postural hypotension (determined through examination by the investigator or designee) or history of severe dizziness or fainting on standing in the opinion of the investigator.
11. Has evidence of a clinically significant 12-lead ECG abnormality.
12. Has an average heart rate \< 60 or \> 100 bpm, systolic blood pressure (BP) \< 90 or \> 140 mmHg, or diastolic BP \< 60 or \> 90 mmHg, measured in 3 sequential positions (supine after 5 minutes; sitting after 1 minute; and standing after 2 minutes) and after the sequence has been completed 3 times.
13. Has a history of alcohol abuse or prescription/illicit drug abuse within the previous 5 years.
14. Has positive results on the urine drug screen or alcohol breath test indicative of drugs of abuse or alcohol use at screening.
15. Is receiving concurrent therapy that can interfere with the evaluation of efficacy or safety, such as any drug that in the investigator's opinion may exert significant synergistic interactions with dexmedetomidine.
Medications with potential cardiac effects (eg, hypotension, bradycardia) and medications that may cause sedation (such as quetiapine \[Seroquel®\]), are permissible if the subject has been on a stable dose for a minimum of 30 days prior to Screening and the investigator deems it appropriate.
Medications given for the treatment of chronic agitation are permissible if the subject has been on a stable dose for a minimum of 30 days prior to Screening.
16. Uses any natural health products (including chaparral, comfrey, germander, jin bu huan, kava, pennyroyal, skullcap, St. John's wort, or valerian, and excluding vitamins or mineral supplements) within 7 days prior to study drug administration and throughout the study, unless in the opinion of the investigator or designee the product will not interfere with the study procedures or data integrity or compromise the safety of the subject.
17. Had symptoms of an upper respiratory tract infection within 7 days prior to dosing of the study drug.
18. Utilized oral or injectable corticosteroids within 7 days prior to dosing of the study drug (intranasal and topical corticosteroid use during this time period is allowed).
19. Received any investigational product within 30 days prior to dosing of the study drug.
20. Received DMTS in a previous clinical trial.
21. Has a Johns Hopkins Fall Risk Assessment Score of \> 13.
22. In the opinion of the investigator or designee, is considered unsuitable for study entry and/or is unlikely to comply with the study protocol for any reason.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teikoku Pharma USA, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James Song, MS
Role: STUDY_DIRECTOR
Teikoku Pharma USA, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Elixia MA, LLC
Springfield, Massachusetts, United States
Vitalix
Worcester, Massachusetts, United States
BioBehavioral Health
Toms River, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Andy Jean
Role: primary
Matthew Collins
Role: primary
Madison Filtcraft
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TPU-DMT-02-2213
Identifier Type: -
Identifier Source: org_study_id